Sugi Predict

Sugi Predict / Targets / NEU2

NEU2

Sialidase-2 · Q9Y3R4 · NEU2 on Sugi Atlas →

3,716 patent compounds predicted against NEU2, 2,026 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL6018076 SCHEMBL6018076 0.81 15/20
SCHEMBL6018036 SCHEMBL6018036 0.74 15/20
SCHEMBL6017855 SCHEMBL6017855 0.80 14/20
SCHEMBL6017857 SCHEMBL6017857 0.80 14/20
SCHEMBL6017923 SCHEMBL6017923 0.73 14/20
SCHEMBL6017933 SCHEMBL6017933 0.67 14/20
SCHEMBL6017930 SCHEMBL6017930 1.00 13/20
SCHEMBL6018122 SCHEMBL6018122 1.00 13/20
SCHEMBL6018295 SCHEMBL6018295 1.00 13/20
SCHEMBL6018926 SCHEMBL6018926 1.00 13/20
SCHEMBL6017871 SCHEMBL6017871 0.96 13/20
SCHEMBL6018299 SCHEMBL6018299 0.91 13/20
SCHEMBL6018006 SCHEMBL6018006 0.79 13/20
SCHEMBL6018907 SCHEMBL6018907 0.78 13/20
SCHEMBL6018255 SCHEMBL6018255 0.77 13/20
SCHEMBL6017872 SCHEMBL6017872 0.77 13/20
SCHEMBL6019140 SCHEMBL6019140 0.75 13/20
SCHEMBL7117750 SCHEMBL7117750 0.75 13/20
SCHEMBL7117753 SCHEMBL7117753 0.75 13/20
SCHEMBL6018090 SCHEMBL6018090 0.74 13/20

Clinical trials — most relevant to NEU2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Evaluation of The Efficacy of Triazavirin Versus Oseltamivir in Egyptian Patients Infected With COVID-19 PHASE4UNKNOWN
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis PHASE3RECRUITING
Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction, Follow by Dara Consolidation PHASE3UNKNOWN
A Study of Monosialic Gangliosides to Prevent Albumin-bound Paclitaxel Neurotoxicity PHASE2COMPLETED
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis PHASE1/PHASE2RECRUITING
Immunotherapy of Neuroblastoma Patients Using a Combination of Anti-GD2 and NK Cells PHASE1/PHASE2UNKNOWN
Multi-CAR T Cell Therapy for Acute Myeloid Leukemia PHASE1/PHASE2RECRUITING
A Study to Evaluate the Safety and Efficacy of Nizubaglustat (AZ-3102) in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease PHASE2RECRUITING
Multi-Center Study of ManNAc for GNE Myopathy PHASE2ACTIVE_NOT_RECRUITING
A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases PHASE1COMPLETED
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies PHASE1COMPLETED
Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2) nanWITHDRAWN
The Natural History of Sialidosis Type I nanRECRUITING
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML) nanWITHDRAWN
Registry Gangliosidoses nanUNKNOWN
Sialic Acid Supplementation in N-Acetylneuraminic Acid Synthase (NANS) Deficiency nanCOMPLETED
Sialic Acid in Hepatocellular Carcinoma nanNOT_YET_RECRUITING
A Natural History Study of Patients With GNE Myopathy and GNE-Related Diseases nanCOMPLETED
Histoblood Group Antigens as a Risk Factor of Asthma nanCOMPLETED
Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders nanRECRUITING
The Natural History of Alpha-Mannosidosis nanCOMPLETED
Biomarker for Farber Disease (BioFarber) nanWITHDRAWN
Glycosylation in Patients With Galactosaemia nanCOMPLETED
A Retrospective Study to Identify New Omics Biomarkers of Chronic/Persistent Low Back Pain nanCOMPLETED
Is in Vitro Maturation of Oocytes Influenced by the Origin of Gonadotropins Used in Maturation Medium: is There a Difference in Efficiency When Using Urinary Versus Recombinant Produced Follicle Stimulating Hormone and Human Chorionic Gonadotropin nanUNKNOWN
Glycoprotein and Glycan in Tissue and Blood Samples of Patients With Stage IB-IVA Cervical Cancer Undergoing Surgery to Remove Pelvic and Abdominal Lymph Nodes nanCOMPLETED
Immune Biomarkers Related to Bone Pathology in Patients With Type 1 Gaucher Disease nanUNKNOWN
A Natural History of Late Onset Tay-Sachs Disease nanCOMPLETED
Longitudinal Studies of the Glycoproteinoses nanCOMPLETED
Biomarker for Sanfilippo Type A-B-C-D Disease (BioSanfilippo) nanWITHDRAWN

Related proteins — ESM-2 sequence neighbours (a NEU2 binder may also engage these)

ProteinNameSimilarity
Q9JMH3 — 0.991 Q9JMH3 →
Q64393 — 0.990 Q64393 →
Q64627 — 0.987 Q64627 →
Q5RCH4 — 0.975 Q5RCH4 →
Q9JMH7 — 0.972 Q9JMH7 →
NEU3 Sialidase-3 0.969 landscape →
Q99PW5 — 0.967 Q99PW5 →
O43542 — 0.966 O43542 →
Q8VDK1 — 0.965 Q8VDK1 →
O55137 — 0.965 O55137 →
Q7QIL2 — 0.964 Q7QIL2 →
Q3TRM8 — 0.964 Q3TRM8 →
Q8N8Q3 — 0.963 Q8N8Q3 →
Q08DK0 — 0.963 Q08DK0 →
O97859 — 0.963 O97859 →
MARS2 Methionine--tRNA ligase, mitochondrial 0.963 landscape →
Q5M876 — 0.962 Q5M876 →
PLD3 5'-3' exonuclease PLD3 0.962 landscape →
Q8BZL1 — 0.962 Q8BZL1 →
P52785 — 0.962 P52785 →
POLD1 DNA polymerase delta catalytic subunit 0.962 landscape →
P10937 — 0.961 P10937 →
Q9WU47 — 0.961 Q9WU47 →
P51687 — 0.961 P51687 →
Q96IJ6 — 0.961 Q96IJ6 →
Q14BV6 — 0.961 Q14BV6 →
Q04462 — 0.961 Q04462 →
Q5JTZ9 — 0.960 Q5JTZ9 →
A0A5F8AH41 — 0.960 A0A5F8AH41 →
Q7T012 — 0.960 Q7T012 →